Pau Navarro

Pau Navarro

Auto-generated profile, based on publicly available information

Pau Navarro

MRC Human Genetics Unit, University of Edinburgh, Edinburgh, UK

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2014 in Nature Genetics
Verified
Journal Article
Open access
PDF file
AMAnubha Mahajan
Anubha Mahajan
MGMin Jin Go
Min Jin Go
WZWeihua Zhang
Weihua Zhang
JBJennifer E Below
Jennifer E Below
KGKyle J Gaulton
Kyle J Gaulton
AMAndrew P Morris
Andrew P Morris
Andrew Morris, Mark McCarthy, Michael Boehnke and colleagues report a meta-analysis of genome-wide association studies for type 2 diabetes, including 26,488 cases and 83,964 controls from populations of European, east Asian, south Asian and Mexican and Mexican American ancestry. They identify seven loci newly associated with type 2 diabetes and examine the genetic architecture of disease across populations. To further understanding of the genetic basis of type 2 diabetes (T2D) susceptibility, we aggregated published meta-analyses of genome-wide association studies (GWAS), including 26,488 cases and 83,964 controls of European, east Asian, south Asian and Mexican and Mexican American ancestry. We observed a significant excess in the directional consistency of T2D risk alleles across ancestry groups, even at SNPs demonstrating only weak evidence of association. By following up the strongest signals of association from the trans-ethnic meta-analysis in an additional 21,491 cases and 55,647 controls of European ancestry, we identified seven new T2D susceptibility loci. Furthermore, we observed considerable improvements in the fine-mapping resolution of common variant association signals at several T2D susceptibility loci. These observations highlight the benefits of trans-ethnic GWAS for the discovery and characterization of complex trait loci and emphasize an exciting opportunity to extend insight into the genetic architecture and pathogenesis of human diseases across populations of diverse ancestry.

13 May 2012 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
AMAlisa K Manning
Alisa K Manning
MHMarie-France Hivert
Marie-France Hivert
RSRobert A Scott
Robert A Scott
JGJonna L Grimsby
Jonna L Grimsby
NBNabila Bouatia-Naji
Nabila Bouatia-Naji
CLClaudia Langenberg
Claudia Langenberg

12 August 2012 in Nature Genetics
Verified
Journal Article
Open access
PDF file
RSRobert A Scott
Robert A Scott
VLVasiliki Lagou
Vasiliki Lagou
RWRyan P Welch
Ryan P Welch
EWEleanor Wheeler
Eleanor Wheeler
MMMay E Montasser
May E Montasser
IBInês Barroso
Inês Barroso
Jose Florez, Claudia Langenberg, Erik Ingelsson, Inga Prokopenko, Inês Barroso and colleagues perform large-scale association analyses using the Metabochip to gain further insights into the genetic architecture of glucose regulation. They identify 38 new loci influencing 1 or more glycemic traits and show that many of these loci also modify risk of type 2 diabetes. Through genome-wide association meta-analyses of up to 133,010 individuals of European ancestry without diabetes, including individuals newly genotyped using the Metabochip, we have increased the number of confirmed loci influencing glycemic traits to 53, of which 33 also increase type 2 diabetes risk (q < 0.05). Loci influencing fasting insulin concentration showed association with lipid levels and fat distribution, suggesting impact on insulin resistance. Gene-based analyses identified further biologically plausible loci, suggesting that additional loci beyond those reaching genome-wide significance are likely to represent real associations. This conclusion is supported by an excess of directionally consistent and nominally significant signals between discovery and follow-up studies. Functional analysis of these newly discovered loci will further improve our understanding of glycemic control.

23 December 2012 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
LSLifeLines Cohort Study
LifeLines Cohort Study
AKAnna Köttgen
Anna Köttgen
CCCARDIoGRAM Consortium
CARDIoGRAM Consortium
DCDIAGRAM Consortium
DIAGRAM Consortium
ICICBP Consortium
ICBP Consortium
CGChristian Gieger
Christian Gieger

17 April 2014 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
JOJared O'COnnell
Jared O'COnnell
DGDeepti Gurdasani
Deepti Gurdasani
ODOlivier Delaneau
Olivier Delaneau
NPNicola Pirastu
Nicola Pirastu
SUSheila Ulivi
Sheila Ulivi
JMJonathan Marchini
Jonathan Marchini
Many existing cohorts contain a range of relatedness between genotyped individuals, either by design or by chance. Haplotype estimation in such cohorts is a central step in many downstream analyses. Using genotypes from six cohorts from isolated populations and two cohorts from non-isolated populations, we have investigated the performance of different phasing methods designed for nominally ‘unrelated’ individuals. We find that SHAPEIT2 produces much lower switch error rates in all cohorts compared to other methods, including those designed specifically for isolated populations. In particular, when large amounts of IBD sharing is present, SHAPEIT2 infers close to perfect haplotypes. Based on these results we have developed a general strategy for phasing cohorts with any level of implicit or explicit relatedness between individuals. First SHAPEIT2 is run ignoring all explicit family information. We then apply a novel HMM method (duoHMM) to combine the SHAPEIT2 haplotypes with any family information to infer the inheritance pattern of each meiosis at all sites across each chromosome. This allows the correction of switch errors, detection of recombination events and genotyping errors. We show that the method detects numbers of recombination events that align very well with expectations based on genetic maps, and that it infers far fewer spurious recombination events than Merlin. The method can also detect genotyping errors and infer recombination events in otherwise uninformative families, such as trios and duos. The detected recombination events can be used in association scans for recombination phenotypes. The method provides a simple and unified approach to haplotype estimation, that will be of interest to researchers in the fields of human, animal and plant genetics. Every individual carries two copies of each chromosome (haplotypes), one from each of their parents, that consist of a long sequence of alleles. Modern genotyping technologies do not measure haplotypes directly, but the combined sum (or genotype) of alleles at each site. Statistical methods are needed to infer (or phase) the haplotypes from the observed genotypes. Haplotype estimation is a key first step of many disease and population genetic studies. Much recent work in this area has focused on phasing in cohorts of nominally unrelated individuals. So called ‘long range phasing’ is a relatively recent concept for phasing individuals with intermediate levels of relatedness, such as cohorts taken from population isolates. Methods also exist for phasing genotypes for individuals within explicit pedigrees. Whilst high quality phasing techniques are available for each of these demographic scenarios, to date, no single method is applicable to all three. In this paper, we present a general approach for phasing cohorts that contain any level of relatedness between the study individuals. We demonstrate high levels of accuracy in all demographic scenarios, as well as the ability to detect (Mendelian consistent) genotyping error and recombination events in duos and trios, the first method with such a capability.

12 September 2017 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
EWEleanor Wheeler
Eleanor Wheeler
ALAaron Leong
Aaron Leong
CLChing-Ti Liu
Ching-Ti Liu
MHMarie-France Hivert
Marie-France Hivert
RSRona Strawbridge
Rona Strawbridge
JMJames B. Meigs
James B. Meigs
Glycated hemoglobin (HbA1c) is used to diagnose type 2 diabetes (T2D) and assess glycemic control in patients with diabetes. Previous genome-wide association studies (GWAS) have identified 18 HbA1c-associated genetic variants. These variants proved to be classifiable by their likely biological action as erythrocytic (also associated with erythrocyte traits) or glycemic (associated with other glucose-related traits). In this study, we tested the hypotheses that, in a very large scale GWAS, we would identify more genetic variants associated with HbA1c and that HbA1c variants implicated in erythrocytic biology would affect the diagnostic accuracy of HbA1c. We therefore expanded the number of HbA1c-associated loci and tested the effect of genetic risk-scores comprised of erythrocytic or glycemic variants on incident diabetes prediction and on prevalent diabetes screening performance. Throughout this multiancestry study, we kept a focus on interancestry differences in HbA1c genetics performance that might influence race-ancestry differences in health outcomes. Using genome-wide association meta-analyses in up to 159,940 individuals from 82 cohorts of European, African, East Asian, and South Asian ancestry, we identified 60 common genetic variants associated with HbA1c. We classified variants as implicated in glycemic, erythrocytic, or unclassified biology and tested whether additive genetic scores of erythrocytic variants (GS-E) or glycemic variants (GS-G) were associated with higher T2D incidence in multiethnic longitudinal cohorts (N = 33,241). Nineteen glycemic and 22 erythrocytic variants were associated with HbA1c at genome-wide significance. GS-G was associated with higher T2D risk (incidence OR = 1.05, 95% CI 1.04–1.06, per HbA1c-raising allele, p = 3 × 10−29); whereas GS-E was not (OR = 1.00, 95% CI 0.99–1.01, p = 0.60). In Europeans and Asians, erythrocytic variants in aggregate had only modest effects on the diagnostic accuracy of HbA1c. Yet, in African Americans, the X-linked G6PD G202A variant (T-allele frequency 11%) was associated with an absolute decrease in HbA1c of 0.81%-units (95% CI 0.66–0.96) per allele in hemizygous men, and 0.68%-units (95% CI 0.38–0.97) in homozygous women. The G6PD variant may cause approximately 2% (N = 0.65 million, 95% CI 0.55–0.74) of African American adults with T2D to remain undiagnosed when screened with HbA1c. Limitations include the smaller sample sizes for non-European ancestries and the inability to classify approximately one-third of the variants. Further studies in large multiethnic cohorts with HbA1c, glycemic, and erythrocytic traits are required to better determine the biological action of the unclassified variants. As G6PD deficiency can be clinically silent until illness strikes, we recommend investigation of the possible benefits of screening for the G6PD genotype along with using HbA1c to diagnose T2D in populations of African ancestry or groups where G6PD deficiency is common. Screening with direct glucose measurements, or genetically-informed HbA1c diagnostic thresholds in people with G6PD deficiency, may be required to avoid missed or delayed diagnoses.